{"Symbol": "LLY", "AssetType": "Common Stock", "Name": "Eli Lilly and Company", "Description": "Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.", "Exchange": "NYSE", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Drug ManufacturersGeneral", "Address": "Lilly Corporate Center, Indianapolis, IN, United States, 46285", "FullTimeEmployees": "34720", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "143040086016", "EBITDA": "7613300224", "PERatio": "24.3018", "PEGRatio": "1.2891", "BookValue": "4.515", "DividendPerShare": "2.96", "DividendYield": "0.0201", "EPS": "6.15", "RevenuePerShareTTM": "25.228", "ProfitMargin": "0.2448", "OperatingMarginTTM": "0.2783", "ReturnOnAssetsTTM": "0.099", "ReturnOnEquityTTM": "1.5761", "RevenueTTM": "22949799936", "GrossProfitTTM": "17598300000", "DilutedEPSTTM": "6.15", "QuarterlyEarningsGrowthYOY": "0.076", "QuarterlyRevenueGrowthYOY": "-0.024", "AnalystTargetPrice": "165.07", "TrailingPE": "24.3018", "ForwardPE": "20.7039", "PriceToSalesRatioTTM": "5.9354", "PriceToBookRatio": "34.8128", "EVToRevenue": "6.816", "EVToEBITDA": "19.5454", "Beta": "0.2187", "52WeekHigh": "170.75", "52WeekLow": "105.95", "50DayMovingAverage": "155.2578", "200DayMovingAverage": "150.4201", "SharesOutstanding": "956470016", "SharesFloat": "793741717", "SharesShort": "4245999", "SharesShortPriorMonth": "5234378", "ShortRatio": "1.59", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0.0054", "PercentInsiders": "0.153", "PercentInstitutions": "79.608", "ForwardAnnualDividendRate": "2.96", "ForwardAnnualDividendYield": "0.0201", "PayoutRatio": "0.4519", "DividendDate": "2020-09-10", "ExDividendDate": "2020-08-13", "LastSplitFactor": "2:1", "LastSplitDate": "1997-10-16"}